Table 2. Summary of PD-L1-negative HNSCC patient treated with cisplatin.
| HNSCC type | Sex/Age | p16 status | Brief history | Baseline tissue | Baseline PD-L1 | Post-treatment tissue | Post PD-L1 |
|---|---|---|---|---|---|---|---|
| hypopharynx | F/66 | (−) | Induction chemotherapy → definitive CCRT → salvage operation |
Before induction chemotherapy, primary tumor | (−) | On salvage operation, recurred tumor | (−) |
| Hypopharynx | M/63 | (−) | Induction chemotherapy → definitive CCRT → salvage operation |
Before induction chemotherapy. primary tumor | (−) | On salvage operation, recurred tumor | (1+) |
| Pyriform sinus | M/62 | (−) | Induction chemotherapy → definitive operation → post-RT → salvage operation |
Before induction chemotherapy. primary tumor | (−) | On salvage operation, recurred tumor | (1+) |
| Nasal cavity | M/60 | (−) | Definitive CCRT → salvage operation |
Before CCRT, primary tumor | (−) | On salvage operation, recurred tumor | (1+) |
| Larynx | M/66 | (−) | Definitive operation → post-CCRT → salvage operation |
On definitive operation, primary tumor | (−) | On salvage operation, recurred tumor | (1+) |
| Hypopharynx | M/69 | (−) | Induction chemotherapy → definitive CCRT → salvage operation |
Before induction chemotherapy. primary tumor | (−) | On salvage operation, recurred tumor | (1+) |
Abbreviation: HNSCC, head and neck squamous cell carcinoma; CCRT, concurrent chemoradiotherapy; RT, radiotherapy.